Survey of Mast Cell Density in Transitional Cell Carcinoma

Overview

Journal Iran J Pathol

Date 2021 May 3

PMID 33936222

Citations 3

Authors

Hedieh Moradi Tabriz

Maedeh Obohat

Farzan Vahedifard

Arezoo Eftekharjavadi

Affiliations

Soon will be listed here.

Abstract

Background & Objective: Transitional cell carcinoma (TCC) is the world's seventh most common tumor and forms more than 90% of urinary bladder tumors. Invasive tumors are associated with poor prognosis, even with surgical treatment and chemotherapy. Some studies have found that an increase in the number of mast cells in TCC is related to the tumor grade and its aggressiveness. This study investigated the relationship between mast cell density (MCD) and features of TCC (tumor stage, grade, prognosis, and recurrence).

Methods: Fifty-one cases with TCC were selected, and MCD was determined by immunohistochemistry (IHC) and Giemsa staining. Mortality rate and tumor recurrence were recorded.

Results: The MCD mean was higher in high-grade tumors than in low-grade tumors (in IHC method: 9.127 vs 5.296; in Giemsa method: 5.512 vs 2.608). Also, the MCD mean in dead patients was higher than in survived patients (in IHC method: 11.390 vs 6.211; in Giemsa method: 7.460 vs 3.35). Patients with tumor recurrence showed a higher MCD mean than those without recurrence (in IHC method: 9.395 vs 5.475; in Giemsa method: 5.715 vs 2.931).

Conclusion: Using mast cell tryptase and Giemsa, MCD may be associated with a positive correlation with tumor grade in TCC. Correlations between MCD, recurrence, prognosis, and tumor stage are probably caused by the effect of tumor grade (all with <0.05).

Citing Articles

Verification of the expression trend and interaction prediction of innate immune cells and immune-checkpoint molecules in the process of oral mucosal carcinogenesis.

Li K, Shi L, Liu L, Wang J, Nie M, Liu X Hua Xi Kou Qiang Yi Xue Za Zhi. 2024; 42(2):192-206.

PMID: 38597079 PMC: 11034413. DOI: 10.7518/hxkq.2024.2023280.

The Urinary Microbiome: Role in Bladder Cancer and Treatment.

Friedrich V, Choi H Diagnostics (Basel). 2022; 12(9).

PMID: 36140470 PMC: 9497549. DOI: 10.3390/diagnostics12092068.

Imaging More than Skin-Deep: Radiologic and Dermatologic Presentations of Systemic Disorders.

Shafiei M, Zadeh F, Mansoori B, Pyle H, Agim N, Hinojosa J Diagnostics (Basel). 2022; 12(8).

PMID: 36010360 PMC: 9407377. DOI: 10.3390/diagnostics12082011.

References

Sari A, Calli A, Cakalagaoglu F, Aksoy Altinboga A, Bal K . Association of mast cells with microvessel density in urothelial carcinomas of the urinary bladder. Ann Diagn Pathol. 2011; 16(1):1-6. DOI: 10.1016/j.anndiagpath.2011.07.001. View

Stockmann C, Schadendorf D, Klose R, Helfrich I . The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front Oncol. 2014; 4:69. PMC: 3986554. DOI: 10.3389/fonc.2014.00069. View

Serel T, Soyupek S, Candir O . Association between mast cells and bladder carcinoma. Urol Int. 2004; 72(4):299-302. DOI: 10.1159/000077681. View

Ribatti D, Tamma R, Vacca A . Mast Cells and Angiogenesis in Human Plasma Cell Malignancies. Int J Mol Sci. 2019; 20(3). PMC: 6386864. DOI: 10.3390/ijms20030481. View

Ribatti D, Crivellato E . Mast cells, angiogenesis and cancer. Adv Exp Med Biol. 2011; 716:270-88. DOI: 10.1007/978-1-4419-9533-9_14. View

Abern M, Dude A, Tsivian M, Coogan C . The characteristics of bladder cancer after radiotherapy for prostate cancer. Urol Oncol. 2012; 31(8):1628-34. DOI: 10.1016/j.urolonc.2012.04.006. View

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F . Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2016; 71(1):96-108. DOI: 10.1016/j.eururo.2016.06.010. View

Marech I, Ammendola M, Sacco R, Capriuolo G, Patruno R, Rubini R . Serum tryptase, mast cells positive to tryptase and microvascular density evaluation in early breast cancer patients: possible translational significance. BMC Cancer. 2014; 14:534. PMC: 4117953. DOI: 10.1186/1471-2407-14-534. View

Lee J, Joo H, Cho D, Kim S, Ahn H, Kim S . Prognostic Significance of Substaging according to the Depth of Lamina Propria Invasion in Primary T1 Transitional Cell Carcinoma of the Bladder. Korean J Urol. 2012; 53(5):317-23. PMC: 3364470. DOI: 10.4111/kju.2012.53.5.317. View

10.

Rafiemanesh H, Lotfi Z, Bakhtazad S, Ghoncheh M, Salehiniya H . The epidemiological and histological trend of bladder cancer in Iran. J Cancer Res Ther. 2018; 14(3):532-536. DOI: 10.4103/0973-1482.172134. View

11.

Mukai K, Tsai M, Saito H, Galli S . Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev. 2018; 282(1):121-150. PMC: 5813811. DOI: 10.1111/imr.12634. View

12.

Xu W, Qian J, Zeng F, Li S, Guo W, Chen L . Protein kinase Ds promote tumor angiogenesis through mast cell recruitment and expression of angiogenic factors in prostate cancer microenvironment. J Exp Clin Cancer Res. 2019; 38(1):114. PMC: 6404326. DOI: 10.1186/s13046-019-1118-y. View

13.

Ribatti D, Crivellato E . Immune cells and angiogenesis. J Cell Mol Med. 2009; 13(9A):2822-33. PMC: 4498938. DOI: 10.1111/j.1582-4934.2009.00810.x. View

14.

Keser S, Kandemir N, Ece D, Gecmen G, Gul A, Barisik N . Relationship of mast cell density with lymphangiogenesis and prognostic parameters in breast carcinoma. Kaohsiung J Med Sci. 2017; 33(4):171-180. DOI: 10.1016/j.kjms.2017.01.005. View

15.

Kim J, Kang Y, Kim D, Lee C, Jeon Y, Lee N . The relationship between mast cell density and tumour grade in transitional cell carcinoma of the bladder. J Int Med Res. 2011; 39(5):1675-81. DOI: 10.1177/147323001103900509. View

16.

Eder J, Rogojanu R, Jerney W, Erhart F, Dohnal A, Kitzwogerer M . Mast Cells Are Abundant in Primary Cutaneous T-Cell Lymphomas: Results from a Computer-Aided Quantitative Immunohistological Study. PLoS One. 2016; 11(11):e0163661. PMC: 5125565. DOI: 10.1371/journal.pone.0163661. View

17.

Maltby S, Khazaie K, McNagny K . Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta. 2009; 1796(1):19-26. PMC: 2731828. DOI: 10.1016/j.bbcan.2009.02.001. View

18.

Molderings G, Zienkiewicz T, Homann J, Menzen M, Afrin L . Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA. F1000Res. 2017; 6:1889. PMC: 5710302. DOI: 10.12688/f1000research.12730.1. View

19.

Marech I, Ammendola M, Gadaleta C, Zizzo N, Oakley C, Gadaleta C . Possible biological and translational significance of mast cells density in colorectal cancer. World J Gastroenterol. 2014; 20(27):8910-20. PMC: 4112891. DOI: 10.3748/wjg.v20.i27.8910. View

20.

Rajput A, Turbin D, Cheang M, Voduc D, Leung S, Gelmon K . Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 2007; 107(2):249-57. PMC: 2137942. DOI: 10.1007/s10549-007-9546-3. View